<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04138186</url>
  </required_header>
  <id_info>
    <org_study_id>G-IBS_01</org_study_id>
    <nct_id>NCT04138186</nct_id>
  </id_info>
  <brief_title>G-PUR® for Symptomatic Treatment in Irritable Bowel Syndrome With Diarrhea</brief_title>
  <official_title>A Randomized, Placebo Controlled, Double-blind, Parallel-arm Feasibility (Pilot) Study to Evaluate Safety and Clinical Efficacy of G-PUR® Treatment in Patients With Irritable Bowel Syndrome With Diarrhea (IBS-D)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Glock Health, Science and Research GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Glock Health, Science and Research GmbH</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A randomized, double-blind, placebo-controlled pilot study in patients with IBS-D according
      to Rome IV criteria evaluating the clinical efficacy and safety of oral administration of 2g
      G-PUR® tid compared to placebo in a cohort of 30 patients over an active treatment period of
      12 weeks.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 2, 2019</start_date>
  <completion_date type="Anticipated">August 2020</completion_date>
  <primary_completion_date type="Anticipated">August 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The rate of responders for the patient's global assessment of relief using the last four assessments in the treatment period.</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Patient's global assessment of symptom relief measured on a 5-point Likert scale (1= very good and 5= very poor)</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse (and serious) events</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Daily intensity of bloating using a 11-point numerical rating scale (NRS) where 0 represents no bloating discomfort and 10 represents very severe bloating discomfort</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Daily urgency using a 11-point numerical rating scale (NRS) where 0 represents no defecation urgency and 10 represents worst imaginable urgency</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Daily stool frequency</measure>
    <time_frame>12 weeks</time_frame>
    <description>Daily Stool Frequency assessed by daily diary entry of the total number of bowel movements within the last 24 hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient compliance with daily diary reporting</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ePRO usability using a paper questionnaire</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Worst daily abdominal pain using a 11-point NRS</measure>
    <time_frame>12 weeks</time_frame>
    <description>Percentage of responders, defined as the percentage of participants who meet the following criterion for at least 50% of the days with diary entry: Abdominal pain assessed by a 11-point NRS-scale improved at least 30% compared to baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Daily stool consistency using the Bristol Stool Form Scale (Type 1 separate hard lumps, like nuts (hard to pass); Type 7 watery, no solid pieces, entirely liquid)</measure>
    <time_frame>12 weeks</time_frame>
    <description>Percentage of responders, defined as the percentage of participants who have ≥50% reduction in the number of days per week with at least one stool that has a consistency of Type 6 or 7 on the Bristol stool scale compared to baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Responder rate (ie weekly and daily) of the combined endpoint: worst daily abdominal pain and daily stool consistency</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Additional responder analyses (i.e. weekly and daily) of IBS symptoms listed all above evaluating different change in symptom intensity with treatment (i.e., greater than or equal to 30, 40 and 50 percent change in intensity compared with baseline)</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of pain-free days</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of gastrointestinal symptoms using the IBS-SSS during each onsite visit;</measure>
    <time_frame>12 weeks</time_frame>
    <description>Proportion of patients having a reduction ≥ 50 on the IBS-SSS system (ranges 0-500). A decrease in 50 or greater in the IBS-SSS is considered a positive response.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life using validated generic SF12 questionnaire</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital anxiety and depression scale (HADS)</measure>
    <time_frame>12 weeks</time_frame>
    <description>scale measuring anxiety and depression (14 items); likert scale 0 (not at all) to 3 (most of the time); higher scores(summed) indicate presence of anxiety or depression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stress response using the perceived stress questionnaire</measure>
    <time_frame>12 weeks</time_frame>
    <description>The (Perceived Stress Questionnaire) PSQ consists of 30 items, each of which has to be scored by a test person using a Likert scale (1 for &quot;almost never&quot;, 2 for &quot;sometimes&quot;, 3 for &quot;frequently&quot; to 4 for &quot;mostly&quot;) how often each item/sentence applied during the last month. Each number has a point that reveals the level of stress for each sentence. Points are calculated according to the calculation system of the scale, and for each individual, the final calculation results in the total value between 0 and 100. Higher total values indicate more stress</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Use of rescue medication (to be assessed daily)</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Exploratory endpoint: bile acid in stool</measure>
    <time_frame>12 weeks</time_frame>
    <description>bile acid excretion in stool before and after 12 weeks treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Exploratory endpoint: zonulin in stool</measure>
    <time_frame>12 weeks</time_frame>
    <description>zonulin (ng/ml) in stool before and after 12 weeks treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Exploratory endpoint: microbiome in stool</measure>
    <time_frame>12 weeks</time_frame>
    <description>microbiome in stool assessed by 16S gene sequencing before and after 12 weeks treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Exploratory endpoint: HBD2 in stool</measure>
    <time_frame>12 weeks</time_frame>
    <description>human beta defensin 2 (HBD2) (ng/ml) in stool before and after 12 weeks treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Exploratory endpoint: gluten in stool</measure>
    <time_frame>12 weeks</time_frame>
    <description>gluten (ng/ml) in stool before and after 12 weeks treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Exploratory endpoint: IDO in blood</measure>
    <time_frame>12 weeks</time_frame>
    <description>indoleamine-2,3- dioxygenase (IDO) (umol/mmol) in capillary blood before and after 12 weeks treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Exploratory endpoint: zonulin in blood</measure>
    <time_frame>12 weeks</time_frame>
    <description>zonulin (ng/ml) in capillary blood before and after 12 weeks treatment</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Irritable Bowel Syndrome With Diarrhea (IBS-D)</condition>
  <arm_group>
    <arm_group_label>2.0g G-PUR® capsules</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo capsules</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>2.0g G-PUR®, oral administration</intervention_name>
    <description>tid for 12 weeks</description>
    <arm_group_label>2.0g G-PUR® capsules</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Placebo, oral administration</intervention_name>
    <description>tid for 12 weeks</description>
    <arm_group_label>Placebo capsules</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age 18-75 years

          2. Recurrent abdominal pain, at least one day/week in the last 3 months (with symptom
             onset at least 6 months before diagnosis), associated with two or more of the
             following criteria (Rome IV criteria)

               1. Related to defecation

               2. Associated with a change in frequency of stool

               3. Associated with a change in form (appearance) of stool.

          3. Moderate to severe abdominal pain as defined with an IBS Symptoms Severity Scale
             (IBS-SSS) score &gt; 175

          4. Patient reports that abnormal bowel movements are usually diarrhea with more than
             one-fourth (25%) of bowel movements with Bristol stool form types 6 or 7 and less than
             one-fourth (25%) of bowel movements with Bristol stool form types 1 or 2. Starting
             during the screening/run-in phase, all patients will keep diaries of stool frequency
             and consistency. Stool consistency will be assessed according to the Bristol Stool
             Form scale (Lewis and Heaton, 1997)

          5. Stable eating habits, within one month before randomization

          6. In patients &gt; 50 years colonoscopy performed during the past 5 years demonstrates no
             pathology associated with the symptoms reported for IBS

          7. Ability to understand trial instructions and to comply with treatment

          8. Patient agree to be compliant for study interactive web - response system schedule
             confirmed at time of randomization

          9. Written informed consent prior to enrolment

        Exclusion Criteria:

          1. Patient has exclusively constipation-predominant IBS (IBS-C) that is characterized by
             &lt; 3 bowel movements/week or hard and lumpy stools (e.g. Bristol stool form types 1 or
             2)

          2. Patient has irritable bowel syndrome with mixed bowel habits (IBS-M) with varying
             symptoms of constipation and diarrhea

          3. Calprotectin stool value &gt; 200mg/kg stool

          4. Known hypersensitivity to the IMD (known aluminium and/or silicon hypersensitivity)

          5. Patient has failed to record &gt;50% of daily diary entries during run-in period

          6. Rectal bleeding in the absence of documented bleeding hemorrhoids or anal fissures
             assessed by fecal occult blood test

          7. History of major gastric, hepatic, pancreatic or intestinal surgery or perforation
             with exception of appendectomy, cholecystectomy and inguinal hernia

          8. Patients with a history of positive tests for ova, parasites or clostridium difficile
             must undergo repeat testing, which must be negative, during the screening period

          9. Use of the following prohibited medications: any antibiotics including rifaximin
             within the past 2 months or during treatment period, use of cholestyramine during
             entire study period, during run-in phase and during the treatment period any use of
             concomitant medication effecting the gastrointestinal movement and/or function (e.g.
             anticholinergic drugs, 5-HT3 receptor antagonists, prokinetic agents, intestinal flora
             regulating drugs, parasympathetic inhibitors, opioids or eluxadoline)

         10. Use of immunosuppressive drugs within the last 6 months or planned use of
             immunosuppressive drugs during the study

         11. Patients treated with tricyclic antidepressants

         12. Serotonin re-uptake inhibitors are allowed if the patient is at stable dose for at
             least 8 weeks prior to signing informed consent and the dose will remain stable
             throughout the duration of the study.

         13. History of inflammatory or immune-mediated gastrointestinal (GI) disorders including
             inflammatory bowel disease (i.e., Crohn's disease, ulcerative colitis) and celiac
             disease (by anamnesis and assessed by tTGA levels)

         14. Active infection, or abnormalities in laboratory testing, vital signs, or physical
             examination at screening

         15. Participation in any other interventional clinical trial within 4 weeks before study
             participation

         16. Alcohol or drug abuse (History of alcohol abuse or heavy alcohol use as binge drinking
             on 5 or more days per month within the 12 months prior to screening. Known medication
             and drug abuse)

         17. Pregnant or breastfeeding (for all females, negative pregnancy test at screening and
             at each treatment visit will be performed).

         18. History of cancer (except non-melanoma skin cancer, or carcinoma in situ of cervix)
             within the previous 12 months or treatment with anticancer therapy (chemotherapy,
             immunotherapy, radiotherapy, hormone therapy for cancer treatment, targeted therapy or
             gene therapy) within 12 months before the first administration of investigational
             product or at any time during the study

         19. Patients with known familial colorectal cancer syndromes, where colorectal cancer has
             not been excluded by colonoscopy

         20. Other severe comorbid condition, concurrent medication, or other issue that renders
             the patient unsuitable for participation in the study, including but not limited to:
             comorbid condition with an estimated life expectancy of ≤ 12 months, patients with
             uncontrolled hypothyroidism, uncontrolled hyperthyroidism, patients on dialysis,
             patients with severe pulmonary (requiring home oxygen, uncontrolled COPD Gold III/ IV)
             or cardiovascular conditions (heart failure NYHA III and IV, uncontrolled hypertension
             systolic BP by repeated measurement &gt; 180 mmHg; patient with uncontrolled diabetes
             with an Hba1c &gt;6.5%)

         21. Concomitant psychotherapy is allowed if the patient started therapy for at least 8
             weeks prior to signing informed consent and the schedule will remain stable throughout
             the duration of the study.

         22. Known severe psychiatric disorders or mental condition rendering the patient unable to
             understand the nature, scope and possible consequences of the study;

         23. Presence of any condition that impacts compliance with the study procedures

         24. Employee at the study site, spouse/partner or relative of any study staff (e.g.
             investigator, sub-investigators, or study nurse) or relationship to the sponsor)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Wolzt, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Clinical Pharmacology, Medical University of Vienna</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Michael Wolzt, Prof. Dr.</last_name>
    <phone>+43 (0)1 40400</phone>
    <phone_ext>2981</phone_ext>
    <email>michael.wolzt@meduniwien.ac.at</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of Clinical Pharmacology, Medical University of Vienna</name>
      <address>
        <city>Vienna</city>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Wolzt, Prof. Dr.</last_name>
      <phone>+43 (0)1 40400</phone>
      <phone_ext>2981</phone_ext>
      <email>michael.wolzt@meduniwien.ac.at</email>
    </contact>
    <investigator>
      <last_name>Michael Wolzt, Prof. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>October 16, 2019</study_first_submitted>
  <study_first_submitted_qc>October 23, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 24, 2019</study_first_posted>
  <last_update_submitted>October 23, 2019</last_update_submitted>
  <last_update_submitted_qc>October 23, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 24, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>IBS</keyword>
  <keyword>Diarrhea</keyword>
  <keyword>Gastrointestinal function disorder</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Irritable Bowel Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Diarrhea</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

